An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.Patient information: no further patient information was provided by the customer.This report is being filed on an international product, list number 2k91-78 that has a similar product distributed in the us, list number 2k91-33.
|
The customer observed a falsely decreased architect ca 19-9xr results for 1 patient.The following data was provided for a patient diagnosed with chronic lymphocyte proliferation, with an unknown pancreatic cancer history: initial result = >1200 ng/ml, repeat automatic dilution 1:10 = 2167.43 ng/ml, repeat manual dilution 1:20 = 4657.6 ng/ml.No impact to patient management was reported.
|
After further evaluation, the suspect medical device was changed from architect ca19-9xr, list number 02k91-78, manufacturing site abbott wiesbaden, deu in this report to architect i2000sr processing module, list number 03m74-02, manufacturing site abbott irving, tx.Mdr number 1628664-2019-00693 has been submitted and all further information will be documented under that mdr number.
|